HK1092137A1 - Xanthine derivatives as a2b adenosine receptor antagonists - Google Patents
Xanthine derivatives as a2b adenosine receptor antagonistsInfo
- Publication number
- HK1092137A1 HK1092137A1 HK06108745.5A HK06108745A HK1092137A1 HK 1092137 A1 HK1092137 A1 HK 1092137A1 HK 06108745 A HK06108745 A HK 06108745A HK 1092137 A1 HK1092137 A1 HK 1092137A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- receptor antagonists
- adenosine receptor
- xanthine derivatives
- xanthine
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2003/014085 WO2004106337A1 (en) | 2003-05-06 | 2003-05-06 | Xanthine derivatives as a2b adenosine receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1092137A1 true HK1092137A1 (en) | 2007-02-02 |
Family
ID=33488737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK06108745.5A HK1092137A1 (en) | 2003-05-06 | 2006-08-07 | Xanthine derivatives as a2b adenosine receptor antagonists |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1622908B1 (de) |
JP (1) | JP2006515316A (de) |
CN (1) | CN100590125C (de) |
AT (1) | ATE403656T1 (de) |
AU (1) | AU2003249604B2 (de) |
CA (1) | CA2524778C (de) |
CY (1) | CY1108457T1 (de) |
DE (1) | DE60322748D1 (de) |
DK (1) | DK1622908T3 (de) |
ES (1) | ES2311759T3 (de) |
HK (1) | HK1092137A1 (de) |
MX (1) | MXPA05011860A (de) |
NZ (1) | NZ543416A (de) |
PT (1) | PT1622908E (de) |
SI (1) | SI1622908T1 (de) |
WO (1) | WO2004106337A1 (de) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006138376A1 (en) * | 2005-06-16 | 2006-12-28 | Cv Therapeutics, Inc. | Prodrugs of a2b adenosine receptor antagonists |
ES2270715B1 (es) | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
ES2274712B1 (es) | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
US20070208040A1 (en) * | 2006-03-02 | 2007-09-06 | Elfatih Elzein | A2a adenosine receptor antagonists |
WO2009088518A1 (en) * | 2008-01-11 | 2009-07-16 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists for the treatment of cancer |
US8871751B2 (en) | 2008-01-18 | 2014-10-28 | The Board Of Trustees Of The University Of Illinois | Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer |
EP2268641B1 (de) | 2008-03-26 | 2014-09-03 | Advinus Therapeutics Pvt. Ltd. | Heterocyclische verbindungen als adenosinrezeptorantagonist |
WO2009157938A1 (en) * | 2008-06-26 | 2009-12-30 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists for treating cancer |
US8859566B2 (en) | 2009-03-13 | 2014-10-14 | Advinus Therapeutics Private Limited | Substituted fused pyrimidine compounds |
WO2011055391A1 (en) | 2009-11-09 | 2011-05-12 | Advinus Therapeutics Private Limited | Substituted fused pyrimidine compounds, its preparation and uses thereof |
JP5827998B2 (ja) * | 2010-09-13 | 2015-12-02 | アドヴィナス・セラピューティックス・リミテッド | A2bアデノシン受容体アンタゴニストのプロドラッグとしてのプリン化合物、これらの方法および薬剤の適用 |
CN105143229B (zh) | 2013-03-15 | 2017-06-30 | 海德拉生物科学有限公司 | 取代的黄嘌呤及其使用方法 |
ES2580702B1 (es) | 2015-02-25 | 2017-06-08 | Palobiofarma, S.L. | Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina |
EP3389664A4 (de) * | 2015-12-14 | 2020-01-08 | Raze Therapeutics Inc. | Koffeininhibitoren von mthfd2 und verwendungen dafür |
JP7295034B2 (ja) * | 2017-05-05 | 2023-06-20 | アーカス バイオサイエンシズ インコーポレイティド | 癌関連障害の治療のためのキナゾリン-ピリジン誘導体 |
SG11202008611UA (en) * | 2018-03-05 | 2020-10-29 | Teon Therapeutics Inc | Adenosine receptor antagonists and uses thereof |
CA3126735A1 (en) | 2019-01-11 | 2020-07-16 | Omeros Corporation | Methods and compositions for treating cancer |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8510758D0 (en) * | 1985-04-27 | 1985-06-05 | Wellcome Found | Compounds |
DE3843117A1 (de) * | 1988-12-22 | 1990-06-28 | Boehringer Ingelheim Kg | Neue xanthinderivate mit adenosin-antagonistischer wirkung |
JPH06102662B2 (ja) * | 1989-09-01 | 1994-12-14 | 協和醗酵工業株式会社 | キサンチン誘導体 |
WO1995011681A1 (en) * | 1993-10-29 | 1995-05-04 | Merck & Co., Inc. | Human adenosine receptor antagonists |
DE19535504A1 (de) * | 1995-09-25 | 1997-03-27 | Bayer Ag | Substituierte Xanthine |
US6117878A (en) * | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
ES2189079T3 (es) * | 1998-04-24 | 2003-07-01 | Leuven K U Res & Dev | Efectos inmunosupresores de derivados de xantina 8-sustituidos. |
US6545002B1 (en) * | 1999-06-01 | 2003-04-08 | University Of Virginia Patent Foundation | Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors |
DK1401837T3 (da) * | 2001-06-29 | 2005-11-07 | Cv Therapeutics Inc | Purinderivater som A2B-adenosinreceptorantagonister |
CN100467469C (zh) * | 2001-11-09 | 2009-03-11 | Cv医药有限公司 | A2b腺苷受体拮抗剂 |
BR0302965A (pt) * | 2002-02-01 | 2005-02-09 | King Pharmaceuticals Res & Dev | Composto e método de tratar doenças mediadas por receptores de adenosina a2b |
-
2003
- 2003-05-06 AU AU2003249604A patent/AU2003249604B2/en not_active Ceased
- 2003-05-06 ES ES03817096T patent/ES2311759T3/es not_active Expired - Lifetime
- 2003-05-06 WO PCT/US2003/014085 patent/WO2004106337A1/en active Application Filing
- 2003-05-06 SI SI200331355T patent/SI1622908T1/sl unknown
- 2003-05-06 MX MXPA05011860A patent/MXPA05011860A/es active IP Right Grant
- 2003-05-06 DK DK03817096T patent/DK1622908T3/da active
- 2003-05-06 CN CN03826411A patent/CN100590125C/zh not_active Expired - Fee Related
- 2003-05-06 PT PT03817096T patent/PT1622908E/pt unknown
- 2003-05-06 AT AT03817096T patent/ATE403656T1/de active
- 2003-05-06 JP JP2005500296A patent/JP2006515316A/ja active Pending
- 2003-05-06 NZ NZ543416A patent/NZ543416A/en not_active IP Right Cessation
- 2003-05-06 CA CA2524778A patent/CA2524778C/en not_active Expired - Fee Related
- 2003-05-06 DE DE60322748T patent/DE60322748D1/de not_active Expired - Lifetime
- 2003-05-06 EP EP03817096A patent/EP1622908B1/de not_active Expired - Lifetime
-
2006
- 2006-08-07 HK HK06108745.5A patent/HK1092137A1/xx not_active IP Right Cessation
-
2008
- 2008-10-27 CY CY20081101212T patent/CY1108457T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
WO2004106337A1 (en) | 2004-12-09 |
MXPA05011860A (es) | 2006-02-17 |
EP1622908B1 (de) | 2008-08-06 |
AU2003249604A1 (en) | 2005-01-21 |
CA2524778A1 (en) | 2004-12-09 |
CY1108457T1 (el) | 2014-04-09 |
CA2524778C (en) | 2013-01-29 |
SI1622908T1 (sl) | 2008-12-31 |
DE60322748D1 (de) | 2008-09-18 |
CN100590125C (zh) | 2010-02-17 |
NZ543416A (en) | 2009-01-31 |
JP2006515316A (ja) | 2006-05-25 |
ATE403656T1 (de) | 2008-08-15 |
CN1771250A (zh) | 2006-05-10 |
ES2311759T3 (es) | 2009-02-16 |
PT1622908E (pt) | 2008-11-14 |
AU2003249604B2 (en) | 2011-06-30 |
DK1622908T3 (da) | 2008-11-17 |
EP1622908A1 (de) | 2006-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1092137A1 (en) | Xanthine derivatives as a2b adenosine receptor antagonists | |
WO2005105803A3 (en) | Purine derivatives as a1 adenosine receptor antagonists | |
MXPA03008967A (es) | Antagonistas receptores de 8-heteroarilo xantina adenosina a-2b. | |
AP2005003452A0 (en) | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors. | |
WO2005021548A3 (en) | Substituted 8-heteroaryl xanthines | |
ZA200705040B (en) | 2,4 (4,6) pyrimidine derivatives | |
EP1723227A4 (de) | Nicotinamidribosid-kinase-zusammensetzungen und verfahren zu deren verwendung | |
DE602005020127D1 (de) | Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors | |
SI3184526T1 (sl) | Derivati pirolo(2,3-D)pirimidina kot inhibitorji Janus kinaze | |
IL174771A0 (en) | Pyrimidin-2-amine derivatives and their use as a2b adenosine receptor antagonists | |
EP1599482A4 (de) | Pyrazolo¬1,5-a pyrimidinderivate | |
HK1088893A1 (en) | Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimidoÄ1,2-aÜ pyrimidin-4-one derivatives | |
AP2006003486A0 (en) | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors. | |
HK1083838A1 (en) | A2a adenosine receptor antagonists | |
AP2005003353A0 (en) | Diazepinoindole derivatives as kinase inhibitors. | |
HK1063780A1 (en) | Adenosine a2a receptor antagonists | |
IL161572A0 (en) | Adenosine a2a receptor antagonists | |
MXPA04000886A (es) | Derivados de triazolil-imidazopiridina y triazolilpurinas empledos como ligandos del receptor de adenosina a2a y su uso como medicamentos. | |
HK1064097A1 (en) | Bicyclic Ä1,2,4Ü -triazole adenosine a2a receptor antagonists | |
SI1622912T1 (sl) | 2-alkinil- in 2-alkenil-pirazolo-(4,3-E)-1,2,4-triazolo-(1,5-C)-pirimidin adenozinski A2a receptorski antagonisti | |
ATE538123T1 (de) | 2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors | |
ZA200408755B (en) | Condensed purine derivatives as A1 adenosine receptor antagonists. | |
MXPA04010267A (es) | Compuestos novedosos. | |
WO2008027585A3 (en) | Pyrrolo[3,2-d]pyrimidines that are selective antagonists of a2b adenosine receptors | |
PL375263A1 (en) | 2,5-substituted pyrimidine derivatives as ccr-3 receptor antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20200504 |